Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

NCT05429632 is registered in ClinicalTrials.gov with Priothera SAS as lead sponsor.

NCT NCT05429632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
Lead sponsor
Priothera SAS
Phase
Phase 3
Overall status
Recruiting
Start date
June 16, 2022
Completion date
November 30, 2029
Enrollment
366 (estimated)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute myeloid leukemia